Drug research

Bevacizumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Avastin

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerNCT07446322	Oncolytics Biotech	Phase 2	Recruiting	2027-08-30Estimated
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809	IBRX	Phase 2	Active not recruiting	2029-12-31Estimated
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationNCT05593328	Cardiff Oncology	Phase 2	Completed	2024-12-09Actual
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598	Replimune, Inc.	Phase 2	Recruiting	2027-12-01Estimated
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308	Cardiff Oncology	Phase 2	Active not recruiting	2026-11Estimated
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258	Tempest Therapeutics	Phase 3	Not yet recruiting	2028-12Estimated
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985	CHRS	Phase 2	Active not recruiting	2027-09Estimated
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666	Jazz Pharmaceuticals	Phase 2	Completed	2025-08-30Actual
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861	CHRS	Phase 2	Completed	2025-06-30Actual

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Oncolytics BiotechRecruitingPrimary completion: 2027-08-30 · Estimated

Trial details

Registry ID: NCT07446322
Phase: Phase 2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

IBRXActive not recruitingPrimary completion: 2029-12-31 · Estimated

Trial details

Registry ID: NCT06061809
Phase: Phase 2

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Cardiff OncologyCompletedPrimary completion: 2024-12-09 · Actual

Trial details

Registry ID: NCT05593328
Phase: Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Replimune, Inc.RecruitingPrimary completion: 2027-12-01 · Estimated

Trial details

Registry ID: NCT05733598
Phase: Phase 2

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Cardiff OncologyActive not recruitingPrimary completion: 2026-11 · Estimated

Trial details

Registry ID: NCT06106308
Phase: Phase 2

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest TherapeuticsNot yet recruitingPrimary completion: 2028-12 · Estimated

Trial details

Registry ID: NCT06680258
Phase: Phase 3

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

CHRSActive not recruitingPrimary completion: 2027-09 · Estimated

Trial details

Registry ID: NCT06679985
Phase: Phase 2

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Jazz PharmaceuticalsCompletedPrimary completion: 2025-08-30 · Actual

Trial details

Registry ID: NCT03929666
Phase: Phase 2

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

CHRSCompletedPrimary completion: 2025-06-30 · Actual

Trial details

Registry ID: NCT05359861
Phase: Phase 2

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.